No open-market selling at Compass Therapeutics, Inc. in the past year, which is unusual. Instead two executives and directors added about $97,000 worth of CMPX.
Anderman Jonathan (Executive Officer) made the biggest buy, worth around $47,000.
Quarter by quarter: 2 quarters in a row of net buying by insiders. Insiders bought in 3 of the last 7 full quarters. Big money check: 216 institutions held CMPX as of Q2 2026, and more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Lerner Neil | Executive Officer | Buy | 20,000 | $0.92 | $18K | SEC |
| Sep 25, 2026 | Lerner Neil | Executive Officer | Buy | 2,500 | $1.14 | $3K | SEC |
| Apr 30, 2026 | Lerner Neil | Executive Officer | Buy | 15,000 | $1.89 | $28K | SEC |
| Apr 30, 2026 | Anderman Jonathan | Executive Officer | Buy | 25,000 | $1.89 | $47K | SEC |
| May 27, 2025 | Schuetz Thomas J. | CEO | Buy | 10,000 | $2.11 | $21K | SEC |
| Apr 11, 2025 | GORDON CARL L | Director | Sell | 3,571,428 | $1.59 | $5.7M | SEC |
| Apr 11, 2025 | OrbiMed Capital GP VI LLC | Director | Sell | 3,571,428 | $1.59 | $5.7M | SEC |
| Apr 8, 2025 | Anderman Jonathan | Officer | Buy | 20,000 | $1.54 | $31K | SEC |
| Apr 8, 2025 | Lerner Neil | Executive Officer | Buy | 20,000 | $1.42 | $28K | SEC |
| Mar 10, 2023 | Schuetz Thomas J. | CEO | Buy | 10,000 | $3.37 | $34K | SEC |
| Feb 27, 2023 | Schuetz Thomas J. | CEO | Buy | 20,000 | $3.98 | $80K | SEC |
| Feb 15, 2023 | Schuetz Thomas J. | CEO | Buy | 20,000 | $3.86 | $77K | SEC |
| Jan 31, 2023 | Schuetz Thomas J. | CEO | Buy | 20,000 | $4.05 | $81K | SEC |
| Jan 24, 2023 | Schuetz Thomas J. | CEO | Buy | 20,000 | $4.19 | $84K | SEC |
In the last 12 months Compass Therapeutics, Inc. insiders made open-market purchases worth about $97,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CMPX was filed on 2026-10-02.
216 investment managers reported holding CMPX in SEC Form 13F filings for Q2 2026.
No congressional trades in CMPX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).